Introduction: Corticosteroid-induced osteoporosis (CIO) is the most common type of secondary osteoporosis, leading to fractures, and increased morbidity and mortality.
Source of data: Pubmed, EMBASE, Scopus and Google Scholar databases.
Areas of agreement: Prolonged glucocorticoids administration leads to secondary osteoporosis.
Areas of controversy: The optimal management for CIO is controversial.
Growing points: The present study compared bone mineral density, fractures and adverse events in patients undergoing treatment with risedronate, alendronate, zoledronate, denosumab or etidronate for CIO.
Areas timely for developing research: For selected patients with CIO, alendronate performed better overall. These results must be interpreted within the limitations of the present study.
Level of evidence: I, Bayesian network meta-analysis of randomized clinical trials.
Keywords: BMD; alendronate; corticosteroid; drugs; fracture; osteoporosis.
© The Author(s) 2022. Published by Oxford University Press.